LSTA
Price
$3.00
Change
-$0.00 (-0.00%)
Updated
Oct 4 closing price
31 days until earnings call
RCUS
Price
$17.10
Change
+$0.45 (+2.70%)
Updated
Oct 7, 02:56 PM (EDT)
29 days until earnings call
Ad is loading...

LSTA vs RCUS

Header iconLSTA vs RCUS Comparison
Open Charts LSTA vs RCUSBanner chart's image
Lisata Therapeutics
Price$3.00
Change-$0.00 (-0.00%)
Volume$2.23K
CapitalizationN/A
Arcus Biosciences
Price$17.10
Change+$0.45 (+2.70%)
Volume$200
CapitalizationN/A
View a ticker or compare two or three
LSTA vs RCUS Comparison Chart
Loading...
LSTA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RCUS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
LSTA vs. RCUS commentary
Oct 07, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LSTA is a Hold and RCUS is a Hold.

COMPARISON
Comparison
Oct 07, 2024
Stock price -- (LSTA: $3.00 vs. RCUS: $16.65)
Brand notoriety: LSTA and RCUS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LSTA: 20% vs. RCUS: 109%
Market capitalization -- LSTA: $24.71M vs. RCUS: $1.41B
LSTA [@Biotechnology] is valued at $24.71M. RCUS’s [@Biotechnology] market capitalization is $1.41B. The market cap for tickers in the [@Biotechnology] industry ranges from $531.34B to $0. The average market capitalization across the [@Biotechnology] industry is $2.87B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LSTA’s FA Score shows that 1 FA rating(s) are green whileRCUS’s FA Score has 0 green FA rating(s).

  • LSTA’s FA Score: 1 green, 4 red.
  • RCUS’s FA Score: 0 green, 5 red.
According to our system of comparison, LSTA is a better buy in the long-term than RCUS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LSTA’s TA Score shows that 3 TA indicator(s) are bullish while RCUS’s TA Score has 5 bullish TA indicator(s).

  • LSTA’s TA Score: 3 bullish, 6 bearish.
  • RCUS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, RCUS is a better buy in the short-term than LSTA.

Price Growth

LSTA (@Biotechnology) experienced а +3.14% price change this week, while RCUS (@Biotechnology) price change was +8.05% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.82%. For the same industry, the average monthly price growth was +2.41%, and the average quarterly price growth was -6.25%.

Reported Earning Dates

LSTA is expected to report earnings on Mar 27, 2025.

RCUS is expected to report earnings on Feb 19, 2025.

Industries' Descriptions

@Biotechnology (+0.82% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RCUS($1.41B) has a higher market cap than LSTA($24.7M). LSTA YTD gains are higher at: 9.941 vs. RCUS (-12.827). LSTA has higher annual earnings (EBITDA): -23.93M vs. RCUS (-235M). RCUS has more cash in the bank: 969M vs. LSTA (38.3M). LSTA has less debt than RCUS: LSTA (176K) vs RCUS (11M). RCUS has higher revenues than LSTA: RCUS (247M) vs LSTA (0).
LSTARCUSLSTA / RCUS
Capitalization24.7M1.41B2%
EBITDA-23.93M-235M10%
Gain YTD9.941-12.827-78%
P/E RatioN/AN/A-
Revenue0247M-
Total Cash38.3M969M4%
Total Debt176K11M2%
FUNDAMENTALS RATINGS
LSTA vs RCUS: Fundamental Ratings
LSTA
RCUS
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
15
Undervalued
56
Fair valued
PROFIT vs RISK RATING
1..100
10075
SMR RATING
1..100
9696
PRICE GROWTH RATING
1..100
5652
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LSTA's Valuation (15) in the null industry is somewhat better than the same rating for RCUS (56) in the Pharmaceuticals Major industry. This means that LSTA’s stock grew somewhat faster than RCUS’s over the last 12 months.

RCUS's Profit vs Risk Rating (75) in the Pharmaceuticals Major industry is in the same range as LSTA (100) in the null industry. This means that RCUS’s stock grew similarly to LSTA’s over the last 12 months.

RCUS's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as LSTA (96) in the null industry. This means that RCUS’s stock grew similarly to LSTA’s over the last 12 months.

RCUS's Price Growth Rating (52) in the Pharmaceuticals Major industry is in the same range as LSTA (56) in the null industry. This means that RCUS’s stock grew similarly to LSTA’s over the last 12 months.

RCUS's P/E Growth Rating (98) in the Pharmaceuticals Major industry is in the same range as LSTA (100) in the null industry. This means that RCUS’s stock grew similarly to LSTA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LSTARCUS
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 4 days ago
90%
Momentum
ODDS (%)
Bearish Trend 4 days ago
86%
Bullish Trend 4 days ago
80%
MACD
ODDS (%)
Bullish Trend 4 days ago
69%
Bearish Trend 4 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 4 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
78%
Advances
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 11 days ago
82%
Declines
ODDS (%)
Bearish Trend 6 days ago
88%
Bearish Trend 5 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
81%
Bearish Trend 4 days ago
74%
View a ticker or compare two or three
Ad is loading...
LSTA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RCUS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IIRLX40.720.39
+0.97%
Voya Russell Large Cap Index Port I
OANIX27.600.23
+0.84%
Oakmark International Institutional
NGDCX27.860.23
+0.83%
Neuberger Berman Large Cap Growth C
OIODX16.64-0.04
-0.24%
AXS Income Opportunities D
FRLAX19.68-0.11
-0.56%
Franklin Real Estate Securities Adv

RCUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with NTLA. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCUS
1D Price
Change %
RCUS100%
+8.75%
NTLA - RCUS
53%
Loosely correlated
+1.93%
PRME - RCUS
51%
Loosely correlated
+2.93%
SNDX - RCUS
50%
Loosely correlated
+0.70%
OCUL - RCUS
50%
Loosely correlated
+6.61%
DNLI - RCUS
50%
Loosely correlated
+1.45%
More